Interview with Vlad Coric, M.D., President & CEO of Biohaven


Here is Renee's interview with Vlad Coric, M.D., President & CEO of Biohaven.

He shares about the history of Biohaven (including their roots right here in Connecticut), their clinical research and drug development, and much more!

Listen here:

Vlad Coric, M.D., President & CEO of Biohaven

Biohaven is a clinical-stage biopharmaceutical company with proven leadership in industry and academic settings. Our portfolio is comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders. Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors.

biohavenpharma.com

In a study of people who took either Nurtec ODT (669 people) or placebo (682 people), more people taking Nurtec ODT experienced pain freedom and freedom from their most bothersome symptom (selected from light sensitivity, sound sensitivity, or nausea) at 2 hours vs placebo. Additionally, more people taking Nurtec ODT experienced freedom from functional disability and pain relief as early as 60 minutes vs placebo. These benefits were sustained through 48 hours for some people.

Photos: Biohaven Pharmaceuticals